The development of a “10-minute cancer test”: the Methylscape

By now, many readers have probably seen news reports coming out of Australia about the “possible medical breakthrough” of a rapid, highly accurate test that can be used to detect cancer anywhere in the body (prostate cancer specifically included). … READ MORE …

Understanding “cell-free DNA analysis” in cancer diagnosis and management

We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …

Prediction of potentially lethal forms of prostate cancer

An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. … READ MORE …

Liquid biopsies, ctDNA, and the diagnosis and management of cancers

The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …

INO-5150 in early treatment of biochemically recurrent prostate cancer

In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). … READ MORE …

Prevalence of DNA-repair germline mutations in men with metastatic prostate cancer

A new study in this week’s New England Journal of Medicine reports that DNA-repair germline mutations were found in nearly 12 percent of patients who had metastatic prostate cancer. … READ MORE …

The accurate assessment of risk profiles among high-risk prostate cancer patients

A key question in management of prostate cancer is the risk that a particular patient has disease — at the time of diagnosis — that will progress over time to become metastatic. The ability to answer this question with accuracy is fundamental to the need for aggressive, early treatment. … READ MORE …